T he natriuretic peptides constitute a family of closely related vasoactive hormones that play an important role in the regulation of cardiovascular, renal, and endocrine homeostasis (1) . Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are produced predominantly in the heart, whereas C-type natriuretic peptide (CNP) is produced in endothelial cells of the vasculature (2) , reproductive tissues (3), growth plate of long bones (4) , and the central nervous system (5) . The natriuretic peptides exert their biologic effects through association with specific membrane-bound receptors. Natriuretic peptide receptor types A and B (NPR-A and NPR-B, respectively) each have a large extracellular ligandbinding domain connected to the intracellular signaling domain through a single membrane-spanning segment. The intracellular domain harbors a noncatalytic, kinase-like region linked to a particulate guanylyl cyclase at the carboxy terminus of the molecule (1) . NPR-A serves as the cognate receptor for both ANP and BNP, whereas NPR-B binds selectively to CNP. Most of the important physiologic activities of these peptides seem to be mediated through activation of these guanylyl cyclase-linked receptors. A third receptor subtype, NPR-C, is thought to function largely, albeit not entirely (6) , as a clearance receptor. Blockade of NPR-C has been shown to increase levels of endogenous natriuretic peptides in circulating plasma (7) .
Vitamin D is a seco-steroid that bears a number of important similarities to hormonal ligands that act through nuclear mechanisms to control gene expression. Its most polar metabolite, 1,25 dihydroxyvitamin D (VD), binds specifically and with high affinity to a member of the nuclear receptor gene family termed the vitamin D receptor (VDR). The liganded VDR, when complexed with its heterodimeric partner, the retinoid X receptor (RXR), associates with specific regulatory elements on DNA called vitamin D response elements (VDRE). One such VDRE, DR3, is a direct repeat of the sequence AGGTCA separated by a three-nucleotide spacer (AGGTCANNNAGGTCA). DR3 displays selectivity in preferentially binding to the VDR-RXR heterodimer versus other nuclear receptor dimeric complexes (8) .
A number of studies have identified VD as a potentially important regulator of BP and cardiovascular homeostasis. The mechanism underlying the inverse relationship between VD levels and BP is not completely understood; however, the recent studies of Li et al. (9) suggest that the renin-angiotensin system may be involved. Using genetically engineered VDR knockout mice, they showed that these animals were hypertensive relative to their VDR ϩ/ϩ littermates and that this increase in BP was accompanied by apparent activation of the plasma renin-angiotensin system (RAS).
The data are equally supportive for an important regulatory role for VD in the heart. Rats made vitamin D-deficient display elevations not only in BP but also in ventricular hypertrophy (10) . The former seems to be related, at least in part, to the attendant hypocalcemia because calcium supplementation corrects the hypertension; however, the cardiac hypertrophy persists. Subsequent studies from the same group indicated that a major component of the hypertrophy seen in vitamin D-deficient animals reflects expansion of the interstitial compartment in the heart (predominantly cardiac fibroblasts) with increased production of extracellular matrix proteins (11) . VD has been shown to reduce endothelin-stimulated ANP and BNP gene expression (markers of myocyte hypertrophy) and transcription in cultured neonatal rat atrial (12) and ventricular (13) myocytes and to suppress the hypertrophic response to endothelin, a well known hypertrophic agonist in the cultured ventricular myocyte model (13) . It is interesting that this suppressive activity seems to require structural features of the VDR that are more typically associated with the activation function of this receptor (14, 15) .
Like the liganded VDR, activated NPR-A has been shown to be both antihypertrophic and antihypertensive (16, 17) in a number of different model systems. In the present study, we explored the possibility that VD might exert beneficial effects on the cardiovascular system through NPR-A. Our findings support this hypothesis in demonstrating that VD increases both the activity of the NPR-A protein and the expression of the NPR-A gene in cultured rat aortic smooth muscle (RASM) cells. 
Materials and Methods

Materials
Culture of Vascular Smooth Muscle Cells
Neonatal RASM cells, originally isolated by P. Lynch at the University of Southern California, were obtained at passage 20 from H. Ives at University of California San Francisco. Cells were cultured at 37°C in a 5% CO 2 -humidified incubator in DMEM supplemented with 10% FBS, 100 units/ml penicillin, 100 g/ml streptomycin, and 2% (vol/vol) broth, tryptose phosphate (18) .
Measurement of ANP-Stimulated cGMP Levels
RASM cells were grown to approximately 80% confluence, then changed to serum-substitute media (19) for 24 h. At that point, cells were treated with 10 Ϫ10 to 10 Ϫ7 M VD for 48 h. For measurement of ANP-stimulated cGMP accumulation, cells were washed three times with prewarmed PBS and incubated with 0.5 ml of DMEM that contained 0.5 mM isobutylmethylxanthine and 10 mM HEPES (pH 7.4) for 10 min at 37°C. 10 Ϫ7 M ANP was added to the medium, and the incubation was continued for another 10 min. The reaction was stopped by the removal of medium and addition of 0.3 ml of 12% TCA. The extraction was continued for 30 min at 4°C. The contents of the plate were collected and centrifuged to pellet particulate material. The supernatant fraction was extracted four times with 0.5 ml of watersaturated ether. cGMP levels were determined by RIA after acetylation of the sample and standard using a commercial antibody and [ 125 I]cGMP as tracer.
RNA Isolation and Northern Blot Analysis
RASM cells were plated in 10-cm dishes, cultured, and treated with VD or the nonhypercalcemic vitamin D analogue RO-25-6760 (20, 21) at different concentrations, as indicated in the individual figure legends. Total RNA was extracted from cells using the RNeasy minikit according to instructions provided by the manufacturer. Total RNA was denatured and separated on a gel that contained 2.2% formaldehyde, transferred to nitrocellulose filters, and hybridized to radiolabeled cDNA as described previously (22) . A 1.2-kb EcoRI fragment of the rat NPR-A cDNA was isolated from vector sequence, radiolabeled using the Primer-it RMT kit (Stratagene), and separated from free nucleotide using NucTrap push columns (Stratagene). The membranes were prehybridized for 30 min at 68°C and hybridized with 32 P-labeled NPR-A cDNA (10 7 cpm/2 ml of hybridization solution) for 1 h at 68°C in hybridization solution provided by Stratagene. All membranes were subsequently stripped and rehybridized with a radiolabeled 1150-bp BamHI/EcoRI fragment of 18S rDNA to permit normalization among samples for differences in RNA loading and/or transfer to the filter. Hybridization signal was detected by autoradiography and quantified using the NIH Image program.
Plasmid Constructions
Ϫ1575 rat NPR-A LUC was generated by cloning 1575 bp of NPR-A 5Ј flanking sequence into BamH1/NarI sites of pFOXLUC vector as described previously (23) . Six of the deletion mutants were generated through the use of convenient restriction sites. In each case, the 3Ј linkage used the NarI site of the pFOXLUC vector. The 5Ј linkage used unique restriction sites (NdeI for Ϫ1290LUC, BclI for Ϫ716LUC, HindIII for Ϫ387LUC, SstII for Ϫ273LUC, and DraII for Ϫ77LUC) for placement in the polylinker of the parent vector. The shortest construct, Ϫ9LUC was generated using an upstream sense oligonucleotide (5Ј-GGGGAT CCTTCTGGCACACTCCTG-3Ј) that incorporated a BamHI site at its 5Ј terminus and a downstream antisense oligonucleotide (5Ј-TAGAG-GATAGAATGGCGCCGG-3Ј) derived from 3Ј linker sequence of pFOXLUC containing the NarI site. A PCR product of appropriate size was restricted with BamHI/NarI and cloned into compatible sites of pFOXLUC. All of the deletion constructs were sequenced to confirm the predicted structure.
Transfection and Luciferase Assay
RASM cells were transfected by electroporation at 250 V and 960 F using 1 g of Ϫ1575 NPR-A LUC with 0.2 g of cytomegalovirus-␤-galactosidase. After transfection, cells were plated on six-well plates in growth medium for 24 h. Medium was then changed to DMEM/serum substitute for the ensuing 24 h, at which point various concentrations of VD, or 10 Ϫ8 M VD at different time intervals, were added. Luciferase activity was measured using the luciferase assay system (Promega). ␤-Galactosidase activity was assayed using the Galactolight Plus chemiluminescence assay (Tropix, Bedford, MA). Luciferase levels were normalized for ␤-galactosidase activity in the individual cultures.
Preparation of Nuclear Extracts
RASM cells were transfected with 5 g of hVDR and hRXR or sham transfected using Lipofectin Reagent (InVitrogen) for 24 h. Cells were changed to serum substitute media and treated with vehicle or 10 Ϫ8 M VD for 48 h. Nuclear extracts were prepared as described previously (24) .
Electrophoretic Mobility Shift Assay
S-labeled hVDR and unlabeled hVDR and hRXR␣ were translated
in vitro using a cell-free translation kit (TNT T7 Quick Master Mix kit; Promega) with [ 35 S]methionine and unlabeled methionine, respectively. Double-stranded DR3 (5Ј-AGCTTCAGGTCAAGGAGGTCA-GAG-3Ј; consensus VDRE half sites indicated in bold letters) and wildtype or mutant oligonucleotides derived from NPR-A promoter sequence spanning the region between Ϫ504 and Ϫ472 were generated for use in the electrophoretic mobility shift assay (EMSA). Two different protocols were used for EMSA.
Protocol 1
Two microliters each of unlabeled recombinant VDR and hRXR␣ or 3 l of RASM cell nuclear extract (see above) were incubated in binding reaction buffer (10 mM HEPES [pH 7.9], 50 mM KCl, 0.2 mM EDTA, 2.5 mM DTT, 10% glycerol, and 0.05% NP-40) that contained 0.5 g of poly(dI-dC) and 32 P-end-labeled, double-stranded oligonucleotide, and 10 nM VD at room temperature for 30 min. For competition experiments, a 10-or 100-fold molar excess of unlabeled, double-stranded oligonucleotide was added to the binding reaction. All samples were resolved on 5% nondenaturing polyacrylamide gels. Gels were dried and exposed to x-ray film.
Protocol 2
Two microliters of 35 S-labeled VDR (synthesized in vitro) was incubated, in the presence of 2 l of unlabeled hRXR␣ and 0.5 g poly(dIdC), with 20 ng of unlabeled, double-stranded DR3 or NPR-A oligonucleotides and 10 nM VD. Reactions were carried out in binding buffer (10 mM NaHPO 4 [pH 7.6], 0.25 mM EDTA, 0.5 mM MgCl 2 , and 5% glycerol) for 20 min at 23°C. DNA-protein complexes were resolved by electrophoresis on 5% nondenaturing polyacrylamide gels run in TEA buffer (67 mM Tris-HCl [pH 7.5], 10 mM EDTA, and 33 mM sodium acetate) at 240 V for 3 h at 4°C. The gel was washed three times with 30% methanol and 10% glacial acetic acid, amplified for 30 min (Amplifier, Amersham Pharmacia Biotech), dried, and subjected to autoradiography.
Site-Directed Mutagenesis
Mutations (M1, M2) were created in Ϫ1575 NPR-A-Luc by sitedirected mutagenesis using a commercial kit (Stratagene). Briefly, mixtures that contained 50 ng of Ϫ1575 NPR-A-Luc, two mutagenic primers, dNTP, and Pfu DNA polymerase were added to the PCR buffer.
PCR was carried out for 18 cycles using 30 s of denaturation at 95°C, 1 min of annealing at 55°C, and 2 min/kb extension at 68°C. After PCR, 1 l of Dpn I was added to the reaction to cut parental DNA template, and 5 l of this digest was used for transformation. Several candidate clones were identified and characterized by DNA sequencing.
Analysis of Renal ANP Activity In Vivo
Under anesthesia (intraperitoneal injection of Brevital sodium 50 mg/kg), a midscapular incision was made and Alzet osmotic minipump was implanted subcutaneously into adult male SpragueDawley rats. In the treatment group, the pumps were loaded with RO-25-6760 (0.8 g/kg per d dissolved in 98% propylene glycol ϩ 2% ethanol). In the control group, pumps were filled out with vehicle alone. The wound was closed with sutures, and the rats were returned to their cages after recovery from anesthesia. Over the ensuing 7 d, they were observed for any signs of calcium toxicity: Tremors, muscle spasms, seizures, anorexia, or weight loss. One week after pump implantation, each rat received an intraperitoneal injection of Inactin (100 mg/kg) to induce anesthesia. Animals were placed on a heated operating table. A tracheotomy was performed, and a segment of PE205 tubing was inserted into the trachea to facilitate clearance of secretions from the upper respiratory tract. The left jugular vein was exposed, and a catheter (PE50) was placed. A solution of normal saline that contained 1 mg/ml BSA was infused continuously at 25 l/min through this catheter. The carotid artery was identified through a small paratracheal incision, and a tapered polyethylene catheter (PE50) was inserted for measurement of arterial pressure with a P23id Statham BP transducer attached to a direct writing recorder. A small catheter (PE10) was inserted into the right ureter near the hilum through a right flank incision for collection of urine from the right kidney. A catheter (PE50 tubing) was sutured into the dome of the urinary bladder via a suprapubic incision for the timed collection of urine from the left kidney. A curved 30-G needle attached to PE10 tubing was inserted into the left renal artery near its takeoff from the aorta through a left flank incision under the rib cage. Prompt reflux of arterial blood into the catheter was used to indicate successful needle placement. After completion of this preparative surgery, the rats received an infusion of normal saline that contained 5% BSA (total volume equal to 0.7% of total body weight) over 15 min to replace surgical fluid losses. BP was measured over the subsequent 30 min, and an average value of the electrical mean was taken to record mean arterial pressure. At that point, ANP (250 fmol/L per min) was infused into the left renal artery for 20 min. Urine was collected from both kidneys in the 20-min period before and during the 20-min period of intrarenal ANP infusion. At the end of study, the rats were killed, blood was collected and processed for measurement of plasma calcium, and the renal inner medulla from both kidneys was isolated for measurement of NPR-A mRNA. Urine volume was determined, and urinary sodium was measured by flame photometry (Model 943; Instrumentation Laboratories, Lexington, MA). Urine samples were then diluted 50-fold before measurement of cGMP (2-l sample) using the method described above. All procedures were approved by the IAUCC at UCSF.
Real-Time PCR Analysis
Total RNA was prepared from frozen inner medullas of control and RO-25-6760 -treated rats using the RNaeasy kit. Two micrograms of total RNA was used to reverse transcribe cDNA using the Clontech reverse transcription kit. Rat NPR-A and glyceraldehyde phosphate dehydrogenase (GAPDH) (25) primer pairs and probes were synthesized by Applied Biosystems. Real-time PCR was performed using Taqman Master mix (A&B Applied Biosystems) with an ABI Prism 7700 (A&B Applied Biosystems). Negative controls without input cDNA were used to assess signal specificity. NPR-A transcript levels were quantified and normalized for GAPDH transcript levels in each sample.
Statistical Analyses
Data were analyzed by ANOVA using Bonferroni test to assess significance.
Results
To determine whether VD has a role in the regulation of NPR-A expression/activity, we examined the functional response of the receptor to ligand (ANP-dependent cGMP generation) in the presence or absence of VD. Forty-eight hours of VD treatment had no effect on basal cGMP levels in RASM cells (Chen et al., data not shown). ANP treatment of control cells led to an approximately fivefold increment in cGMP levels, relative to basal, over a 10-min incubation period. VD pretreatment nearly doubled this response with a net stimulation of cGMP levels of approximately 10-fold after ANP treatment ( Figure  1A) . A similar amplification of the response to ANP was seen after pretreatment with the nonhypercalcemic VD analogue RO-25-6760. This increment in NPR-A activity resulted, at least in part, from an increase in NPR-A gene expression. As shown in Figure 1B , VD pretreatment led to an approximately five-to sixfold increase in steady-state NPR-A mRNA levels. Of note, the nonhypercalcemic analogue RO-25-6760 led to a similar increment (approximately fivefold) in NPR-A mRNA levels in cultured RASM cells ( Figure 1C) .
The increment in gene expression, in turn, seems to reflect an increase in NPR-A gene transcription. As shown in Figure 2 , VD, as well as RO-25-6760, treatment of cultured RASM cells led to a significant increase in the activity of a transfected NPR-A promoter-luciferase reporter construct that was not seen with the transfected background vector (pGL3). This stimulation was ligand dependent (Figure 2A) , VD receptor dependent ( Figure 2B) , and time-dependent ( Figure 2B ) and amplifiable with co-transfected RXR, the heterodimeric partner of VDR ( Figure 2C) .
A series of 5Ј-deletion mutants of the NPR-A promoter, extending from Ϫ1575 to Ϫ77 relative to the transcription start site, were generated and linked to the luciferase reporter. As shown in Figure 3 , mutants that harbored as little as 706 bp of the 5Ј flanking sequence retained the ability to respond to VD; however, the Ϫ387 NPR-A-luciferase mutant displayed no induction with VD treatment. This suggests that the VD-sensitive regulatory element is positioned between Ϫ706 and Ϫ387 in the NPR-A gene promoter.
Examination of the DNA sequence spanning this region for the presence of conventional VD regulatory elements revealed five potential candidates, each displaying moderate to high homology to the DR3 motif (two AGGTCA motifs arrayed as direct repeats and separated by three spacer nucleotides [8] ; Figure 4 ). Double-stranded oligonucleotides spanning each of these regions were incubated with radiolabeled VDR, unlabeled RXR, and the VD ligand (10 Ϫ8 M) and fractionated on nondenaturing polyacrylamide gels to assess potential DNAprotein interactions (i.e., conventional EMSA assay). As shown in Figure 5A , NPR-A-1, which displayed the highest degree of homology to the consensus VDRE (homologous at 9 of 12 positions), failed to interact with the VDR-RXR complex in vitro. Similarly, NPR-A-2 and NPR-A-3 failed to associate with this receptor complex ( Figure 5B) ; however, NPR-A-4 displayed a level of VDR-RXR binding that was readily discernible, albeit at a fraction (approximately 50%) of the intensity seen with the consensus DR3 motif. Binding to radiolabeled NPR-A-4 was almost completely inhibited by a 100-fold molar excess of unlabeled oligonucleotide ( Figure 5C ). Introduction of mutations into the downstream candidate site (NPR-A-4 M1) did not impair the ability of this oligonucleotide to inhibit VDR-RXR binding to NPR-A-4 ( Figure 6A ) (i.e., mutated sequence does not harbor the VDRE). Mutation of the upstream site (NPR-A-4 M2), however, resulted in near complete abrogation of the competition for NPR-A-4 binding to the heterodimeric receptor complex. The latter finding suggests that the liganded VDR-RXR complex binds to the upstream sequence that is targeted by the NPR-A-4 M2 mutation. This was confirmed in direct binding studies as shown in Figure 6B . Ϫ8 M VD for 48 h. In all cases, lysates were generated and luciferase and ␤-gal activities were measured as described in the Materials and Methods section. Experiments were repeated three to six times. **P Ͻ 0.01, *P Ͻ 0.05 versus corresponding control.
Whereas wild-type NPR-A-4 and the M1 mutant associated with radiolabeled VDR in this assay, the M2 mutant was devoid of binding activity.
Binding of VDR to NPR-A-4 did not require ligand; binding of recombinant VDR/RXR to NPR-A-4, if anything, was reduced slightly in the presence of 1,25 dihydroxyvitamin D ( Figure 7A ). It is interesting that this differed from receptor expressed in a transfected cell. As shown in Figure 7B , extracts of cells that were transfected with hVDR plus hRXR showed a modest increase in binding to NPR-A-4 versus untransfected cells; however, the inclusion of ligand resulted in a dramatic increase in binding of the extract to the oligonucleotide, suggesting that other proteins in the extract may serve to stabilize the DNA-VDR/RXR complex.
Extending this analysis to the functional assay, mutation of the M1 site in the context of Ϫ1575 NPR-A luciferase failed to influence the VD-dependent stimulation of this promoter, relative to the wild-type sequence, whereas introduction of the M2 mutation into the same promoter context resulted in complete loss of the VD-dependent stimulation ( Figure 8A) . Noteworthy, the M2 mutation did not prevent induction of the NPR-A promoter by osmotic stimuli such as NaCl or sucrose (22, 26) ( Figure 8B ), indicating that the targeted sequence selectively transduces the response to VD.
To assess the physiologic relevance of the in vitro findings, we attempted to extend these analyses into an in vivo model. We chose a model that we have used previously to examine the effects of ANP infused directly into the renal artery on urinary volume and sodium excretion (27) . This model has the advantage of identifying ANP-induced changes in urinary sodium and water handling independent of changes in peripheral hemodynamics. As shown in Table 1 , pretreatment of animals 35 S-VDR and unlabeled RXR were incubated with unlabeled oligonucleotides encoding a consensus DR3 motif or one of four putative VDRE in the NPR-A promoter. All incubations were carried out in the presence of VD (10 Ϫ8 M). DNA-protein complexes were fractionated by electrophoretic mobility shift assays (EMSA) as described in the Materials and Methods section. (C) Unlabeled VDR and RXR, along with VD, were incubated with 32 P-labeled NPR-A-4 oligonucleotide in the absence or presence of increasing concentrations of unlabeled oligonucleotide (10-or 100-fold molar excess). The reaction complexes were resolved on 5% nondenaturing polyacrylamide gels. The experiments were repeated two to three times. Representative autoradiographs are shown.
with the nonhypercalcemic analogue RO-25-6760 for 7 d had no effect on basal mean arterial pressure relative to control. Serum calcium levels were measured in both the control and the analogue-infused animals. Calcium levels in the RO-25-6760 -treated animals remained in the normal range and were not statistically different from the controls ( Table 1) . Infusion of ANP (250 fmol/kg per min) into the left renal artery had no effect on systemic arterial pressure (Table 1) . It did, however, promote an increase in urinary sodium excretion that was not seen in the contralateral, noninfused kidney ( Figure 9A ). Pretreatment with RO-25-6760 for 7 d resulted in a significant increase in ANP-stimulated urinary sodium excretion in the infused kidney, and this was accompanied by a significant increase in ANP-dependent urinary cGMP levels when compared with the control group ( Figure 9B) . In both instances, the magnitude of the increases (in U Na and Uc GMP ) was larger in the RO-25-6760 -treated versus vehicle-treated rats. A modest elevation in U Na V and U cGMP was seen in urine that was collected from the contralateral kidney, presumably reflecting the effects of peptide that has either found its way into the systemic circulation or refluxed into the aorta from the infusion site. Collectively, these findings support our in vitro data in demonstrating that the VD analogue amplifies the activity of the natriuretic peptides in target cells.
To determine whether the increase in natriuretic peptide activity resulted from increased NPR-A expression, as documented in the in vitro system above, we measured NPR-A mRNA transcripts in inner medulla of control versus RO-25-6760 -treated rats using real-time PCR. As shown in Figure 9C , treatment with RO-25-6760 for 7 d resulted in an approximately twofold increment in NPR-A mRNA levels in the inner medulla. Levels of the GAPDH transcript were essentially un- changed. This suggests that the increment in activity of the liganded NPR-A noted above results from VD-dependent stimulation of NPR-A gene expression.
Discussion
The studies described above provide definitive evidence for transcriptional regulation of a cardiovascular gene by VD and identify an important mechanism through which this hormone may exert salutary effects in the cardiovascular system. Previous studies have suggested regulation of NPR-C expression by glucocorticoids (28) ; however, transcriptional regulation was not documented in those studies, and a specific glucocorticoid responsive element was not identified. The current study demonstrates VD1-dependent stimulation of NPR-A activity as well as NPR-A gene expression. The latter derives from an increase in NPR-A promoter activity that is driven by a solitary VDRE located approximately 495 bp upstream from the transcription start site.
Vitamin D activity is classically described in terms of its calcitropic properties in the intestine, kidney, and bone (29); however, more recently increased attention has been devoted to its ability to regulate physiologic events through pathways independent of those that it uses to control serum calcium and phosphorous concentrations. VD has immune-suppressant and anti-inflammatory properties (30) , it reduces cell proliferation in a variety of in vitro models through mechanisms that are only partially understood (31, 32) , and it seems to play an important role in the growth and development of the epidermis and hair follicle (33, 34) . Data acquired through a number of different experimental and clinical studies indicate that VD also plays an important role in cardiovascular homeostasis. 25-Hydroxyvitamin D levels are inversely related to BP levels in selected forms of rodent (35) and human (36) hypertension, and administration of VD restores BP to normal or near-normal levels (37, 38) . Of note, the recent study of Teng et al. (39) demonstrated improved survival of patients who had ESRD and were on hemodialysis when they were treated with the nonhypercalcemic analogue of VD, paricalcitol, versus VD itself, suggesting the existence of important salutary effects of the seco-steroid that are independent of its calcitropic properties. Because the majority of patients with ESRD die of cardiovascular causes, the inference would be that the benefit accrued secondary to the beneficial cardiovascular effects of these drugs.
True vitamin D-deficiency in the rat is accompanied by acquired hypertension and associated ventricular hypertrophy (10) , although in this model, the BP elevation abates with correction of the attendant hypocalcemia. The recent studies of Li et al. (9) suggest that hypertension results from defective VD action in general, rather than solely from hypocalcemia. In VDR null (Ϫ/Ϫ) mice, systolic BP was elevated approximately 20 mmHg versus controls, and this was associated with activation of the RAS. Because these animals were maintained on a highcalcium diet to prevent the development of hypocalcemia, it seems likely that the BP elevation is at least partially reflective of the defect in VDR signaling. Li et al. also presented data suggesting a direct effect of the liganded VDR on the renin gene promoter, although a discrete functional VDRE was not identified.
NPR-A plays a major role in controlling BP and extracellular fluid volume (1). In fact, the studies of DuBois et al. (40) suggest that most, if not all, of the renal effects of ANP are mediated through this receptor. That it mediates vasodilation, increased urinary excretion of sodium and water, and suppression of myocardial hypertrophy and fibrosis (17) makes it an attractive Ϫ8 M VD for 48 h. Alternatively, 48 h after transfection, cells were treated with 150 mM sucrose or 75 mM NaCl for 24 h. Luciferase and ␤-gal activity was measured. Experiment was repeated three times. **P Ͻ 0.01 versus corresponding control.
candidate as a target of and mediator for VD action. Although this does not exclude a parallel role for VD in suppression of the RAS, it is noteworthy that the liganded NPR-A is also capable of suppressing the RAS at multiple points in the signaling cascade (41) , including inhibition of renin gene expression. Therefore, it is conceivable that at least a portion of the reduction in renin expression could result from enhanced NPR-A expression and activity rather than through a direct liganded VDR-dependent suppression of the renin gene promoter. In fact, Li et al. (42) reported that NPR-A gene expression is reduced in VDR Ϫ/Ϫ mice. Additional studies will be required to assess whether the direct versus indirect model is operative here.
Finally, our previous demonstration that VD suppresses expression and secretion of ANP (12, 13, 43) seems, at first glance, to be physiologically inconsistent with the data presented here, because a reduction in ligand levels would be predicted to offset the increase in receptor activity. However, it is important to point out that the VD-dependent inhibition of ANP expression is largely confined to hypertrophy-dependent expression (e.g., that induced by endothelin treatment) and reflects a global antagonism of the hypertrophic process rather than isolated inhibition of the ANP gene. Activation of the ANP gene in hypertrophy represents an attempt, oftentimes futile (44) , to reverse the hemodynamic stimuli that elicit the increase in myocardial mass and through primary (16, 17) as well as secondary (1) effects control further progression of the hypertrophic process. On the basis of its ability to increase NPR-A activity, VD would be predicted to support ANP effects in this setting. Thus, the VD effects may be viewed as consistently aligned toward suppression of growth and hypertrophy in the cardiovascular system. In summary, we have shown that the vasodilatory, antimitogenic receptor NPR-A is under the transcriptional regulatory control of 1,25 dihydroxyvitamin D. This effect may be responsible for a major component of the salutary effects that vitamin D exerts in the cardiovascular system. Urinary cGMP levels were measured in aliquots of urine as described in the Materials and Methods section. Control cGMP levels were 533 Ϯ 53 pmol/ml urine. (C) Real-time PCR analysis of NPR-A mRNA levels in rat inner medulla. Paired inner medullas from control and RO-25-6760 -treated rats were isolated and snap-frozen in liquid nitrogen. Total RNA was prepared and reverse transcribed into cDNA. Real-time PCR was carried out as described in the Materials and Methods section. Pooled data (n ϭ 8) are shown. **P Ͻ 0.01, *P Ͻ 0.05 versus ANP-infused control; ϩ P Ͻ 0.01 versus corresponding control.
